{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:04:00Z","timestamp":1784099040146,"version":"3.55.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Child Adolesc. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>3q29 deletion syndrome is a rare genomic disorder characterized by a broad spectrum of neurodevelopmental and psychiatric manifestations, including developmental delay (DD), intellectual disability (ID), autism spectrum disorder (ASD), attention-deficit\/hyperactivity disorder (ADHD), and a markedly increased lifetime risk of psychosis and schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We describe a 17-year-old female adolescent with severe congenital heart disease and longstanding neurodevelopmental impairment who developed early-onset recurrent psychotic symptoms. Chromosomal microarray analysis identified a\n                      <jats:italic>de novo<\/jats:italic>\n                      heterozygous 1.6 Mb deletion at the 3q29 locus. The emergence of psychotic symptoms served as the pivotal clinical trigger for genetic investigation in the absence of distinctive dysmorphic findings. Combination therapy with lurasidone and olanzapine led to sustained clinical stabilization over a one-year follow-up period, allowing gradual dose adjustment and functional reintegration through adapted educational and recreational activities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early-onset psychotic symptoms in adolescents with neurodevelopmental comorbidities may represent a critical clinical indicator of underlying pathogenic copy number variants, including 3q29 deletion syndrome, even in the absence of highly recognizable dysmorphic features. Increased clinical awareness may facilitate consideration of early genetic testing in this clinical profile to support precision-informed diagnostic evaluation, treatment planning and multidisciplinary management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frcha.2026.1823061","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:05:10Z","timestamp":1784095510000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Early-onset psychosis as a sentinel manifestation of 3q29 deletion syndrome in an adolescent with neurodevelopmental disorders"],"prefix":"10.3389","volume":"5","author":[{"given":"W.","family":"Vidal","sequence":"first","affiliation":[{"name":"Department of Mental Health, Vall D'Hebron University Hospital","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Masotto","sequence":"additional","affiliation":[{"name":"Medical Genetics Group, Vall D'Hebron Research Institute (VHIR)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vi\u00f1as-Jornet","sequence":"additional","affiliation":[{"name":"Medical Genetics Group, Vall D'Hebron Research Institute (VHIR)","place":["Barcelona, Spain"]},{"name":"Department of Clinical and Molecular Genetics, Vall D'Hebron University Hospital","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Ramos-Quiroga","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Vall D'Hebron University Hospital","place":["Barcelona, Spain"]},{"name":"Psychiatry, Mental Health and Addictions Group, Vall D'Hebron Research Institute (VHIR)","place":["Barcelona, Spain"]},{"name":"Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III (ISCIII)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Espa\u00f1ol-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Vall D'Hebron University Hospital","place":["Barcelona, Spain"]},{"name":"Psychiatry, Mental Health and Addictions Group, Vall D'Hebron Research Institute (VHIR)","place":["Barcelona, Spain"]},{"name":"Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III (ISCIII)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1086\/431653","article-title":"3q29 Microdeletion syndrome: clinical and molecular characterization of a new syndrome","volume":"77","author":"Willatt","year":"2005","journal-title":"Am J Hum Genet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ajmg.a.37537","article-title":"Novel features of 3q29 deletion syndrome: results from the 3q29 registry","volume":"170","author":"Glassford","year":"2016","journal-title":"Am J Med Genet A"},{"key":"B3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12920-019-0497-4","article-title":"Familial inheritance of the 3q29 microdeletion syndrome: case report and review","volume":"12","author":"Khan","year":"2019","journal-title":"BMC Med Genomics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1002\/ajmg.a.33573","article-title":"Autistic and psychiatric findings associated with the 3q29 microdeletion syndrome: case report and review","author":"Quintero-Rivera","year":"2010","journal-title":"Am J Med Genet A"},{"key":"B5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/jir.13094","article-title":"Adaptive behaviour deficits in individuals with 3q29 deletion syndrome","volume":"68","author":"Pollak","year":"2024","journal-title":"J Intellect Disabil Res"},{"key":"B6","article-title":"3q29 Recurrent deletion","volume-title":"GeneReviews\u00ae","author":"Mulle","year":"2016"},{"key":"B7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/MCD.0000000000000077","article-title":"A clinical case report and literature review of the 3q29 microdeletion syndrome","volume":"24","author":"Cox","year":"2015","journal-title":"Clin Dysmorphol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/mp.2015.76","article-title":"The 3q29 deletion confers >40-fold increase in risk for schizophrenia","volume":"20","author":"Mulle","year":"2015","journal-title":"Mol Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41436-020-01053-1","article-title":"Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care","volume":"23","author":"Sanchez Russo","year":"2021","journal-title":"Genet Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/ajmg.a.35754","article-title":"Co-occurrence of autism, childhood psychosis, and intellectual disability associated with a de novo3q29 microdeletion","volume":"161","author":"Sagar","year":"2013","journal-title":"Am J Med Genet A"},{"key":"B11","doi-asserted-by":"publisher","first-page":"115867","DOI":"10.1016\/j.psychres.2024.115867","article-title":"Psychosis spectrum symptoms among individuals with schizophrenia-associated copy number variants and evidence of cerebellar correlates of symptom severity","volume":"335","author":"Sefik","year":"2024","journal-title":"Psychiatry Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jir.12919","article-title":"A distinct cognitive profile in individuals with 3q29 deletion syndrome","volume":"67","author":"Klaiman","year":"2023","journal-title":"J Intellect Disabil Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.schres.2020.08.012","article-title":"Treatment-resistant psychotic symptoms and early-onset dementia: a case report of the 3q29 deletion syndrome","volume":"224","author":"Harner","year":"2020","journal-title":"Schizophr Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000531747","article-title":"Response to treatment in 3q29 deletion syndrome-associated psychosis: a mini-review","volume":"82","author":"Colijn","year":"2023","journal-title":"Neuropsychobiology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fped.2019.00270","article-title":"A novel 3q29 deletion in association with developmental delay and heart malformation\u2014case report with literature review","volume":"7","author":"Chirita Emandi","year":"2019","journal-title":"Front Pediatr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ajmg.b.32406","article-title":"A novel 3q29 deletion associated with autism, intellectual disability, psychiatric disorders, and obesity","author":"Biamino","year":"2016","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"B17","volume-title":"The Role of Genetic Testing in Mental Health Settings. College Report CR237","year":"2023"},{"key":"B18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41436-019-0686-8","article-title":"Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American college of medical genetics and genomics (ACMG) and the clinical genome resource (ClinGen)","volume":"22","author":"Riggs","year":"2020","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1755-8166-1-8","article-title":"Expanding the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the reciprocal microduplication","volume":"1","author":"Ballif","year":"2008","journal-title":"Mol Cytogenet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/cap.2021.0092","article-title":"Clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis","volume":"32","author":"Adnan","year":"2022","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","article-title":"A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia","volume":"36","author":"Correll","year":"2022","journal-title":"CNS Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/cap.2016.0189","article-title":"Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study","volume":"27","author":"Goldman","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1192\/j.eurpsy.2022.11","article-title":"Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-na\u00efve vs. Previously treated adolescents with an acute exacerbation of schizophrenia","volume":"65","author":"Correll","year":"2022","journal-title":"Eur Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00787-019-01425-2","article-title":"Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis","volume":"29","author":"Arango","year":"2020","journal-title":"Eur Child Adolesc Psychiatry"}],"container-title":["Frontiers in Child and Adolescent Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frcha.2026.1823061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:05:11Z","timestamp":1784095511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frcha.2026.1823061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":24,"alternative-id":["10.3389\/frcha.2026.1823061"],"URL":"https:\/\/doi.org\/10.3389\/frcha.2026.1823061","relation":{},"ISSN":["2813-4540"],"issn-type":[{"value":"2813-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1823061"}}